JP2003528890A - 胃腸管の炎症性疾患の処置におけるｃｄ２５結合分子の使用 - Google Patents

胃腸管の炎症性疾患の処置におけるｃｄ２５結合分子の使用

Info

Publication number
JP2003528890A
JP2003528890A JP2001571776A JP2001571776A JP2003528890A JP 2003528890 A JP2003528890 A JP 2003528890A JP 2001571776 A JP2001571776 A JP 2001571776A JP 2001571776 A JP2001571776 A JP 2001571776A JP 2003528890 A JP2003528890 A JP 2003528890A
Authority
JP
Japan
Prior art keywords
binding molecule
gastrointestinal tract
tyr
treatment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001571776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003528890A5 (cg-RX-API-DMAC7.html
Inventor
ハンスイェルク・アダム
ロタール・フェルバー
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2003528890A publication Critical patent/JP2003528890A/ja
Publication of JP2003528890A5 publication Critical patent/JP2003528890A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2001571776A 2000-03-30 2001-03-28 胃腸管の炎症性疾患の処置におけるｃｄ２５結合分子の使用 Pending JP2003528890A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0007911.1 2000-03-30
GBGB0007911.1A GB0007911D0 (en) 2000-03-30 2000-03-30 Organic compounds
PCT/EP2001/003541 WO2001072845A1 (en) 2000-03-30 2001-03-28 Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract

Publications (2)

Publication Number Publication Date
JP2003528890A true JP2003528890A (ja) 2003-09-30
JP2003528890A5 JP2003528890A5 (cg-RX-API-DMAC7.html) 2008-05-22

Family

ID=9888901

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001571776A Pending JP2003528890A (ja) 2000-03-30 2001-03-28 胃腸管の炎症性疾患の処置におけるｃｄ２５結合分子の使用

Country Status (18)

Country Link
US (2) US20050226872A1 (cg-RX-API-DMAC7.html)
EP (1) EP1268553A1 (cg-RX-API-DMAC7.html)
JP (1) JP2003528890A (cg-RX-API-DMAC7.html)
KR (2) KR20020084107A (cg-RX-API-DMAC7.html)
CN (1) CN1416432A (cg-RX-API-DMAC7.html)
AU (2) AU2001246516B2 (cg-RX-API-DMAC7.html)
BR (1) BR0109549A (cg-RX-API-DMAC7.html)
CA (1) CA2401249A1 (cg-RX-API-DMAC7.html)
GB (1) GB0007911D0 (cg-RX-API-DMAC7.html)
HU (1) HUP0301846A3 (cg-RX-API-DMAC7.html)
IL (1) IL151089A0 (cg-RX-API-DMAC7.html)
NO (1) NO20024579L (cg-RX-API-DMAC7.html)
NZ (1) NZ520547A (cg-RX-API-DMAC7.html)
PL (1) PL357014A1 (cg-RX-API-DMAC7.html)
RU (1) RU2286797C2 (cg-RX-API-DMAC7.html)
SK (1) SK13892002A3 (cg-RX-API-DMAC7.html)
WO (1) WO2001072845A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200207736B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502593A (ja) * 2001-04-06 2005-01-27 ユニバーシティ・オブ・ブリストル ステロイド耐性患者におけるｃｄ２５結合分子の使用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009086197A1 (en) * 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
EP2438442B1 (en) 2008-12-01 2017-08-09 Laboratory Corporation of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
US20100233732A1 (en) * 2009-01-15 2010-09-16 Laboratory Corporation Of America Holdings Methods of Determining Patient Response By Measurement of HER-2 Expression
BRPI1007321A2 (en) 2009-01-15 2018-07-10 Laboratory Corporation Of America Holdings methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody.
RU2500427C2 (ru) * 2010-07-15 2013-12-10 Олег Ильич Эпштейн Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
WO2000006604A2 (en) * 1998-07-27 2000-02-10 Novartis Ag Use of cd25 binding molecules in the treatment of rheumatoid arthritis or skin diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
WO2000006604A2 (en) * 1998-07-27 2000-02-10 Novartis Ag Use of cd25 binding molecules in the treatment of rheumatoid arthritis or skin diseases

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502593A (ja) * 2001-04-06 2005-01-27 ユニバーシティ・オブ・ブリストル ステロイド耐性患者におけるｃｄ２５結合分子の使用
JP2009102367A (ja) * 2001-04-06 2009-05-14 Univ Of Bristol ステロイド耐性患者におけるｃｄ２５結合分子の使用

Also Published As

Publication number Publication date
RU2286797C2 (ru) 2006-11-10
NO20024579D0 (no) 2002-09-24
IL151089A0 (en) 2003-04-10
PL357014A1 (en) 2004-07-12
AU2001246516B2 (en) 2005-06-30
CA2401249A1 (en) 2001-10-04
NZ520547A (en) 2005-04-29
RU2002127800A (ru) 2004-03-27
WO2001072845A1 (en) 2001-10-04
US20050226872A1 (en) 2005-10-13
SK13892002A3 (sk) 2003-05-02
HUP0301846A3 (en) 2010-07-28
CN1416432A (zh) 2003-05-07
KR20080079702A (ko) 2008-09-01
ZA200207736B (en) 2003-05-08
EP1268553A1 (en) 2003-01-02
KR20020084107A (ko) 2002-11-04
GB0007911D0 (en) 2000-05-17
NO20024579L (no) 2002-11-11
US20090041775A1 (en) 2009-02-12
HUP0301846A2 (hu) 2003-09-29
BR0109549A (pt) 2003-06-10
AU4651601A (en) 2001-10-08

Similar Documents

Publication Publication Date Title
US20090041775A1 (en) Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract
TW201902514A (zh) Ｐｄ－１抗體與ｖｅｇｆ配體或ｖｅｇｆ受體抑制劑聯合在製備治療腫瘤的藥物中的用途
JP2001508441A (ja) 抗ｃｄ４０ｌ化合物での狼瘡腎炎の処置
JP2021130668A (ja) 多発性骨髄腫（ｍｍ）の処置
JP2015013887A (ja) アタシセプトなどのＴＡＣＩ−Ｉｇ融合タンパク質を用いた自己免疫疾患を治療するための投薬法
JP2022163078A (ja) 移植片対宿主病予防の方法
WO2017165125A1 (en) Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer
JP2022548627A (ja) 骨髄線維症の治療のための、高親和性のリガンドを遮断するヒト化抗ｔ細胞免疫グロブリンドメイン及びムチンドメイン３（ｔｉｍ－３）ｉｇｇ４抗体の使用
WO2021155840A1 (zh) 抗pd-1抗体在治疗恶性肿瘤中的用途
AU2001246516A1 (en) Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract
JP2003528890A5 (cg-RX-API-DMAC7.html)
EP4654985A2 (en) Methods and compositions for combination therapy
CN111629731A (zh) 治疗癌症的组合物和方法
TWI870363B (zh) 使用抗ｃｄ１２３免疫結合物之治療方法
US20240182581A1 (en) Methods for the treatment of chronic pouchitis
AU2018274749A1 (en) Methods for the treatment of chronic pouchitis
JP3973360B2 (ja) 関節リウマチまたは皮膚疾患の処置に使用するためのｃｄ２５結合分子
WO2021180027A1 (zh) 抗pd-1抗体和多受体酪氨酸激酶抑制剂的药物组合及其使用方法
CZ20032672A3 (cs) CD25 vazebná molekula pro použití při prevenci nebo léčení některých nemocí u pacientů rezistentních na léčbu steroidy
JP2003508448A (ja) 自己免疫疾患を処置するための方法および組成物
KR20210060582A (ko) 화농성 한선염 치료를 위한 범-elr+ cxc 케모카인 항체
RU2822135C2 (ru) Способы лечения хронического резервуарного илеита
TW202613167A (zh) 使用抗ｔｌ１ａ抗體治療發炎性腸病之方法
WO2026094824A1 (ja) Ｐａｄ阻害剤の自己免疫性関節炎の治療または予防のための使用
Hayman 17 syndromes: management and follow-up

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110419